Latest News

Kaplan Fox Reminds GoDaddy Inc. (GDDY) Investors of an Approaching Securities Class Action Deadline on October 20, 2026 Ready to Announce with Confidence?

Kaplan Fox Reminds Beta Bionics, Inc. (BBNX) Investors to Seek a Leadership Role Before Deadline on November 3, 2026 Ready to Announce with Confidence?

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of The Marygold Companies, Inc. (NYSE American: MGLD)

FTZ entscheidet sich für Zilliant, nachdem Echtzeit-Benchmark überlegene Pricing-Performance bei hoher Skalierung bestätigt

QFIN Investors Have Opportunity to Lead Qfin Holdings, Inc. Securities Fraud Lawsuit

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Class Action Alert: Levi & Korsinsky Reminds Doximity, Inc. (DOCS) Investors of November 16, 2026 Deadline

Class Action Alert: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of November 2, 2026 Deadline

Capstone Partners Releases 2026 Middle Market Business Owners Research Survey: CEOs Acclimate to Volatility and Exhibit Optimism, Exit Preparation Bolsters Decision Making and Business Performance

Mirum Pharmaceuticals annonce que le critère d’évaluation principal a été atteint dans l’étude de phase III AZURE-1 portant sur le brelovitug dans le traitement de l’infection chronique par le virus de l’hépatite D (VHD)